Trilokesh D Kidambi1, Divyanshoo R Kohli2, N Jewel Samadder3, Aparajita Singh4. 1. Division of Gastroenterology, City of Hope National Medical Center, Duarte, CA, USA. 2. Division of Gastroenterology, Kansas City Veterans Affair Medical Center, Kansas City, MO, USA. 3. Division of Gastroenterology and Hepatology, Department of Clinical Genomics, Mayo Clinic, Phoenix, AZ, USA. 4. Division of Gastroenterology, University of California San Francisco, 505 Parnassus Ave, Room S357, San Francisco, CA, 941943, USA. Aparajita.Singh@ucsf.edu.
Abstract
PURPOSE OF REVIEW: Colorectal cancer (CRC) is the third most common cancer in the USA and inherited cancer syndromes are responsible for approximately 3-5% of all CRCs. Genetic testing costs have plummeted in recent years; however, awareness and referral of high-risk patients for testing is still very low. We review the salient clinical features, genetics, and management of well-defined gastrointestinal (GI) hereditary polyposis syndromes including familial adenomatous polyposis, MUTYH-associated polyposis, and the hamartomatous polyposis syndromes. RECENT FINDINGS: Comprehensive endoscopic surveillance has the potential to prevent the development of GI cancer and to identify early-stage cancer; newer developments like high-definition endoscopes, chromoendoscopy, and the use of cap-assisted endoscopy have shown promise for enhanced lesion detection rates. Several chemoprevention trials have yielded promising results but safety and efficacy data for long-term use is still awaited. Several new polyposis genes have also been identified in the recent years. Multiple societies have recently published updated surveillance guidelines to aid clinicians in the detection and management of patients with hereditary GI polyposis syndromes. Although these syndromes are rare, it is crucial for the clinicians to recognize these in a timely manner, for the appropriate management plans for both the patient and their at risk family members.
PURPOSE OF REVIEW: Colorectal cancer (CRC) is the third most common cancer in the USA and inherited cancer syndromes are responsible for approximately 3-5% of all CRCs. Genetic testing costs have plummeted in recent years; however, awareness and referral of high-risk patients for testing is still very low. We review the salient clinical features, genetics, and management of well-defined gastrointestinal (GI) hereditary polyposis syndromes including familial adenomatous polyposis, MUTYH-associated polyposis, and the hamartomatous polyposis syndromes. RECENT FINDINGS: Comprehensive endoscopic surveillance has the potential to prevent the development of GI cancer and to identify early-stage cancer; newer developments like high-definition endoscopes, chromoendoscopy, and the use of cap-assisted endoscopy have shown promise for enhanced lesion detection rates. Several chemoprevention trials have yielded promising results but safety and efficacy data for long-term use is still awaited. Several new polyposis genes have also been identified in the recent years. Multiple societies have recently published updated surveillance guidelines to aid clinicians in the detection and management of patients with hereditary GI polyposis syndromes. Although these syndromes are rare, it is crucial for the clinicians to recognize these in a timely manner, for the appropriate management plans for both the patient and their at risk family members.
Authors: J-C Saurin; B Napoleon; G Gay; T Ponchon; J-P Arpurt; C Boustiere; J Boyer; J-M Canard; P-A Dalbies; J Escourrou; M Greff; J Lapuelle; R Laugier; J-C Letard; B Marchetti; L Palazzo; D Sautereau; B Vedrenne Journal: Endoscopy Date: 2005-05 Impact factor: 10.093
Authors: F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus Journal: N Engl J Med Date: 1993-05-06 Impact factor: 91.245
Authors: Sushrut S Thiruvengadam; Rocio Lopez; Margaret O'Malley; Lisa LaGuardia; James M Church; Matthew Kalady; R Matthew Walsh; Carol A Burke Journal: Gastrointest Endosc Date: 2018-08-03 Impact factor: 9.427
Authors: N Jewel Samadder; Deborah W Neklason; Kenneth M Boucher; Kathryn R Byrne; Priyanka Kanth; Wade Samowitz; David Jones; Sean V Tavtigian; Michelle W Done; Therese Berry; Kory Jasperson; Lisa Pappas; Laurel Smith; Danielle Sample; Rian Davis; Matthew K Topham; Patrick Lynch; Elena Strait; Wendy McKinnon; Randall W Burt; Scott K Kuwada Journal: JAMA Date: 2016 Mar 22-29 Impact factor: 56.272
Authors: Claire Palles; Jean-Baptiste Cazier; Kimberley M Howarth; Enric Domingo; Angela M Jones; Peter Broderick; Zoe Kemp; Sarah L Spain; Estrella Guarino; Estrella Guarino Almeida; Israel Salguero; Amy Sherborne; Daniel Chubb; Luis G Carvajal-Carmona; Yusanne Ma; Kulvinder Kaur; Sara Dobbins; Ella Barclay; Maggie Gorman; Lynn Martin; Michal B Kovac; Sean Humphray; Anneke Lucassen; Christopher C Holmes; David Bentley; Peter Donnelly; Jenny Taylor; Christos Petridis; Rebecca Roylance; Elinor J Sawyer; David J Kerr; Susan Clark; Jonathan Grimes; Stephen E Kearsey; Huw J W Thomas; Gilean McVean; Richard S Houlston; Ian Tomlinson Journal: Nat Genet Date: 2012-12-23 Impact factor: 38.330
Authors: Andrea Mafficini; Lodewijk A A Brosens; Maria L Piredda; Cristian Conti; Paola Mattiolo; Giulia Turri; Maria G Mastrosimini; Sara Cingarlini; Stefano F Crinò; Matteo Fassan; Paola Piccoli; Michele Simbolo; Alessia Nottegar; Rita T Lawlor; Alfredo Guglielmi; Aldo Scarpa; Corrado Pedrazzani; Claudio Luchini Journal: Fam Cancer Date: 2022-01-25 Impact factor: 2.375